 |
 |
---------------------------------------------------------------------------- PD AND HORMONES PART SIX ---------------------------------------------------------------------------- a brief selection from Medscape/Medline on line: http://www5.medscape.com/default.mhtml -----32--------------------------------------------------------------------- Title: Hormones and Parkinson's disease [letter; comment] ---------------------------------------------------------------------------- Title Abreviation: Neurology Date of Pub: 1995 May Author: Giladi N; Honigman S; Issue/Part/Supplement: 5 Volume Issue: 45 Pagination: 1028-9 MESH Headings: Case Report; Female; Hormones (*PH); Human; Levodopa (TU); Menstrual Cycle (*PH); Middle Age; Parkinson Disease (DT/*PP); -RN-; Journal Title Code: NZ0 Publication Type: COMMENT Date of Entry: 950615N Entry Month: 9508 Country: UNITED STATES Index Priority: 1 Language: Eng Unique Identifier: 95265174 ISSN: 0028-3878 Last Revision Date: 950807 -----33-------------------------------------------------------------------- Title: Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period ---------------------------------------------------------------------------- [see comments] Title Abreviation: Neurology Date of Pub: 1993 May Author: Mizuta E; Yamasaki S; Nakatake M; Kuno S; Issue/Part/Supplement: 5 Volume Issue: 43 Pagination: 1048-9 MESH Headings: Body Temperature; Carbidopa (*TU); Case Report; Drug Combinations; Female; Human; Levodopa (*TU); Menstrual Cycle (*); Middle Age; Neuroleptic Malignant Syndrome (ET/*PP); Parkinson Disease (CO/DT/*PP); -RN-; Journal Title Code: NZ0 Publication Type: JOURNAL ARTICLE Date of Entry: 930611N Entry Month: 9308 Country: UNITED STATES Index Priority: 1 Language: Eng Unique Identifier: 93261586 ISSN: 0028-3878 Abstract: A 45-year-old woman with Parkinson's disease developed neuroleptic malignant syndrome (NMS) despite lack of levodopa withdrawal. She experienced two episodes characterized by indomethacin-resistant hyperthermia, hyperhidrosis, and aggravation of parkinsonism. The symptoms, however, disappeared during menstruation. We suggest that the development of NMS may depend, in part, upon the hormonal state. Abstract By: Author Address: Department of Neurology, Utano National Hospital, Kyoto, Japan. Last Revision Date: 950807 -----34--------------------------------------------------------------------- Title: Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease. ---------------------------------------------------------------------------- Title Abreviation: Mov Disord Date of Pub: 1993 Apr Author: Factor SA; Issue/Part/Supplement: 2 Volume Issue: 8 Pagination: 240-1 MESH Headings: Acetazolamide (*AD); Adult; Carbidopa (AD/AE); Case Report; Drug Administration Schedule; Drug Therapy, Combination; Female; Human; Levodopa (AD/AE); Menstruation Disorders (*DT); Neurologic Examination (DE); Parkinson Disease (*DT); Support, Non-U.S. Gov't; -RN-; Journal Title Code: NIA Publication Type: JOURNAL ARTICLE Date of Entry: 930518N Entry Month: 9307 Country: UNITED STATES Index Priority: 2 Language: Eng Unique Identifier: 93233716 ISSN: 0855-3185 Address: Department of Neurology, Albany Medical College, New York. -----35--------------------------------------------------------------------- Title: Estrogens and Parkinson's disease. ---------------------------------------------------------------------------- Title Abreviation: Med Hypotheses Date of Pub: 1994 Apr Author: Session DR; Pearlstone MM; Jewelewicz R; Kelly AC; Issue/Part/Supplement: 4 Volume Issue: 42 Pagination: 280-2 MESH Headings: Adult; Case Report; Estrogens (*PH); Female; Human; Leuprolide (AD); Parkinson Disease (*PP/TH); Premenopause (DE); -RN-; Journal Title Code: M0M Publication Type: JOURNAL ARTICLE Date of Entry: 940926N Entry Month: 9412 Country: ENGLAND Index Priority: 2 Language: Eng Unique Identifier: 94352251 ISSN: 0306-9877 Abstract: There is substantial evidence that estrogens modulate the activity of dopamine in the extrapyramidal system. However, there is conflicting data as to the exact mechanism of estrogen's effects. The majority of clinical reports support an antidopaminergic effect of estrogens on Parkinsonian symptoms. Generally, Parkinsonism worsens with estrogen therapy. We report a case of improvement in Parkinsonian symptoms in a premenopausal patient when placed on leuprolide acetate. The pharmacologic menopause induced by leuprolide acetate leads to a hypoestrogenic state. We hypothesize that the decrease in estrogen improves Parkinson's disease symptoms via the relief of its antidopaminergic effects on the nigrostriatal pathway. Abstract By: Author Address: Department of Obstetrics and Gynecology, Columbia-Presbyterian Medical Center, New York, New York 10032. -----36--------------------------------------------------------------------- Title: The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. ---------------------------------------------------------------------------- Title Abreviation: Anticancer Drugs Date of Pub: 1995 Jun Author: Johnson DE; Ochieng J; Evans SL; Issue/Part/Supplement: 3 Volume Issue: 6 Pagination: 471-4 MESH Headings: Breast Neoplasms (*DT/ME); Cell Division (DE); Dopamine Agonists (*PD); Estradiol (PD); Haloperidol (PD); Human; Prolactin (ME); Receptors, Estrogen (DE/ME); Support, U.S. Gov't, P.H.S.; SK&F-38393 (*PD); Tamoxifen (PD); Tumor Cells, Cultured; -RN-; Journal Title Code: A9F Publication Type: JOURNAL ARTICLE Date of Entry: 951017N Entry Month: 9512 Country: ENGLAND Index Priority: 2 Language: Eng Unique Identifier: 95399823 ISSN: 0959-4973 Abstract: Dopamine agonists have been indicated as treatment for disorders such as Parkinson's disease, cardiogenic shock and dopamine insufficiency. A unique relationship exists between dopamine and carcinogenicity. Chronic prolactin stimulation has been identified as a promoter of carcinogenicity. Prolactin secretion is regulated through dopamine receptor activation. Dopaminergic agonists inhibit prolactin release and antagonists increase release. High levels of prolactin have been shown to suppress production of estrogen and progesterone. As a result of these findings, a series of experiments were designed to examine the effects of a specific dopamine agonist, SKF 38393, against MCF-7 cells. MDA-MB231 and MCF-10 cells were used as negative controls. The breast cancer in vitro screening procedure involved the plating of MCF-7, MDA-MB231 and MCF-10 cells in a 96-well plate assay. After 1 day, the cells were exposed to SKF 38393 for 2 days and cell growth was determined by the Alamar blue dye reagent method. The optical density data was analyzed and IC50 values determined. The results indicated that SKF 38393 caused a significant decrease in proliferation of MCF-7 cells. The IC50 value was 0.1 +/- 0.03 microM. The results also indicated no significant effect on MDA-MB231 and MCF-10 cells. Abstract By: Author Address: Department of Pharmacology, Meharry Medical College, Nashville, TN 37208, USA. -----37--------------------------------------------------------------------- Title: Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. ---------------------------------------------------------------------------- Title Abreviation: Exp Neurol Date of Pub: 1994 Feb Author: McDermott JL; Liu B; Dluzen DE; Issue/Part/Supplement: 2 Volume Issue: 125 Pagination: 306-11 MESH Headings: Animal; Corpus Striatum (*ME); Dopamine (*ME); Estrogens (*PD); Female; Male; Mice; Potassium (PD); Sex Characteristics (*); Substantia Nigra (ME); 3,4-Dihydroxyphenylacetic Acid (*ME); Journal Title Code: EQF Publication Type: JOURNAL ARTICLE Date of Entry: 940323N Entry Month: 9405 Country: UNITED STATES Index Priority: 1 Language: Eng Unique Identifier: 94148054 ISSN: 0014-4886 Abstract: In the present study, we directly compare striatal dopamine metabolism in gonadectomized male and female CD-1 mice treated with 2 days of estrogen or oil vehicle. Basal and potassium-stimulated dopamine and 4-dihydroxyphenylacetic acid (DOPAC) release from in vitro superfused striatum as well as pre- and postsuperfusion tissue dopamine contents were measured. Both basal and potassium-stimulated dopamine release were significantly higher and DOPAC release was significantly lower in males than in females. However, striatal tissue dopamine content was lower in males than in females. Estrogen-treated female mice showed increased basal and potassium-stimulated dopamine release compared to oil-treated females without affecting tissue dopamine content. Estrogen did not affect striatal dopamine concentrations or release in males. These results demonstrate clear sex differences in striatal dopamine turnover and concentrations under conditions of equal hormonal status. The results also indicate that estrogen can exert substantial effects on striatal dopamine metabolism by acting specifically in females to increase neuronal dopamine synthesis and release without depleting dopamine content. These results have important implications for the observed sex differences in clinical movement disorders such as Parkinson's disease. Abstract By: Author Address: Department of Medicine, Case Western Reserve University, Cleveland, Ohio 44106. -----38--------------------------------------------------------------------- Title: Sexual differences in sensitivity to methamphetamine toxicity. ---------------------------------------------------------------------------- Title Abreviation: J Neural Transm Gen Sect Date of Pub: 1993 Author: Wagner GC; Tekirian TL; Cheo CT; Issue/Part/Supplement: 1 Volume Issue: 93 Pagination: 67-70 MESH Headings: Animal; Corpus Striatum (ME); Dopamine (ME); Female; Male; Methamphetamine (*TO); Mice; Mice, Inbred Strains; Nervous System (*DE); Sex Characteristics (*); -RN-; Journal Title Code: AJ2 Publication Type: JOURNAL ARTICLE Date of Entry: 931020N Entry Month: 9312 Country: AUSTRIA Index Priority: 2 Language: Eng Unique Identifier: 93384770 Unique Identifier: 93384770 SSN: -HEADING- Abstract: Male and female mice were treated with methamphetamine (10.0 mg/kg/injection for four injections) and sacrificed two weeks later. It was observed that the methamphetamine treatment caused depletions in striatal dopamine which were significantly greater in males (74%) than in females (56%). These results indicate that estrogen may have a protective effect against methamphetamine-induced dopamine depletions and may relate to the fact that males are more likely to incur Parkinson's disease than females. Abstract By: Author Address: Department of Psychology, Rutgers University, New Brunswick, NJ. -----39--------------------------------------------------------------------- Title: Sarcopenia in aging humans: the impact of menopause and disease. ---------------------------------------------------------------------------- Title Abreviation: J Gerontol A Biol Sci Med Sci Date of Pub: 1995 Nov Author: Poehlman ET; Toth MJ; Fishman PS; Vaitkevicius P; Gottlieb SS; Fisher ML; Fonong T; Issue/Part/Supplement: -HEADING- Volume Issue: 50 Spec No Pagination: 73-7 MESH Headings: Adipose Tissue (ME/PP); Aged; Aged, 80 and over; Aging (ME/*PH); Body Composition (*PH); Case-Control Studies; Disease (*); Energy Metabolism; Female; Heart Failure, Congestive (CO/ME/PP); Human; Menopause (ME/*PH); Middle Age; Muscle, Skeletal (ME/*PP); Muscular Atrophy (ET); Parkinson Disease (CO/ME/PP); Support, U.S. Gov't, P.H.S.; Weight Loss; -AA-; Journal Title Code: CBA Publication Type: JOURNAL ARTICLE Date of Entry: 960111N Entry Month: 9603 Country: UNITED STATES Index Priority: 1 Language: Eng Unique Identifier: 96067374 ISSN: 1079-5006 Abstract: We examine the association of the menopause transition, congestive heart failure, and Parkinson's disease on body composition and energy expenditure. We present evidence suggesting that the normal menopausal transition is associated with accelerated loss of fat-free mass, a decline in resting metabolic rate, and increased central body fatness. Second, we show that the cardiac cachexia associated with heart failure is partially due to an levated level of energy expenditure. Despite having a lower quantity of fat-free mass, congestive heart failure patients have a higher resting metabolic rate approximately 283 kcal/d) for their metabolic size than healthy elderly. The elevated level of resting energy expenditure probably contributes to their unexplained weight loss. Parkinson's patients experience muscular rigidity and tremor which could contribute to inappropriately high levels of energy expenditure and difficulty in maintaining body weight and composition. We examined resting metabolic rate and body composition in eight Parkinson's patients and 34 healthy age-matched controls. Parkinson's patients showed lower levels of fat-free mass (approximately 6 kg), but similar resting metabolic rates (1601 +/- 250 kcal/d) versus healthy controls (1671 +/- 212 kcal/d), suggesting a hypermetabolic state. A re-examination of daily energy needs and the metabolic factors contributing to periods of energy imbalance during the menopausal transition and in several disease states may be a prerequisite to offsetting accelerated sarcopenia. Abstract By: Author Address: Department of Medicine, GRECC, Baltimore VA Medical Center, University of Maryland, USA. Number of References: 25 ---------------------------------------------------------------------------- [log in to unmask]